<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842501</url>
  </required_header>
  <id_info>
    <org_study_id>GOLO1703</org_study_id>
    <nct_id>NCT03842501</nct_id>
  </id_info>
  <brief_title>Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind placebo-controlled study was intended to measure the effects of&#xD;
      the GWMP with Release supplement versus GWMP with placebo supplement in a representative&#xD;
      group of obese subjects with or without diabetes at one outpatient medical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">December 24, 2018</completion_date>
  <primary_completion_date type="Actual">December 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1C from baseline</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Release supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Release Supplement</intervention_name>
    <description>Calorie reduced diet plus Release supplement</description>
    <arm_group_label>Release supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calorie reduced diet plus Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years and ≤ 80 years&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 30 and ≤ 60 kg/m2&#xD;
&#xD;
          3. Have the ability to engage in at least 15 minutes of moderate physical activity such&#xD;
             as brisk walking&#xD;
&#xD;
          4. Willing to comply with study procedures described herein&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current diagnosis of type 1 diabetes&#xD;
&#xD;
          2. Subjects with a history of hypoglycemia&#xD;
&#xD;
          3. A history of an eating disorder as defined by the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fifth Edition (DSM-5)&#xD;
&#xD;
          4. Known allergy to any of the components in the Release supplement&#xD;
&#xD;
          5. A history of prior surgery for weight loss&#xD;
&#xD;
          6. Currently taking injectable medications to control diabetes, including insulin and&#xD;
             GLP-1 agonists&#xD;
&#xD;
          7. Currently pregnant or breastfeeding or have had a baby within the last six weeks&#xD;
&#xD;
          8. Planning to become pregnant in the next three months. Women of child bearing potential&#xD;
             must be willing and able to use adequate and reliable contraception throughout the&#xD;
             study (e.g. abstinence or barrier with additional spermicidal foam or jelly, or the&#xD;
             use of intrauterine device or hormonal contraception).&#xD;
&#xD;
          9. Uncontrolled hypertension at screening defined as Systolic blood pressure greater than&#xD;
             180 mmHG or Diastolic blood pressure greater than 110 mmHG&#xD;
&#xD;
         10. Current clinical diagnosis or signs and symptoms of unstable (in the opinion of the&#xD;
             principle investigator) heart, kidney or liver disease, cancer, or chronic&#xD;
             neurological disease.&#xD;
&#xD;
         11. Current participation in any other weight loss or weight management program&#xD;
&#xD;
         12. Currently taking weight loss medications, or medications or supplements known to be&#xD;
             associated with significant weight loss or weight gain&#xD;
&#xD;
         13. Has any condition that, in the opinion of the investigator, would make participation&#xD;
             in this study not in the best interest of the subject or that could prevent, limit or&#xD;
             confound the protocol-specified assessments. Examples include: history of diabetic&#xD;
             ketoacidosis; active chronic liver disease or cirrhosis; chronic autoimmune disease;&#xD;
             inflammatory bowel disease, colonic ulceration, partial intestinal obstruction,&#xD;
             subjects predisposed to intestinal obstruction; chronic intestinal diseases associated&#xD;
             with marked disorders of digestion or absorption&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Buynak Clinical Research</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

